Abstract	JJ	0	0	0	0	1	0	0	O
The	DT	0	0	0	0	1	0	0	O
canine	JJ	0	0	0	0	0	0	1	O
parvovirus	NN	0	0	0	0	0	0	1	B-protein
NS1	NN	0	1	0	0	1	0	0	I-protein
(	-LRB-	0	0	0	0	0	0	0	I-protein
CPV2.NS1	NN	0	1	0	0	1	0	0	I-protein
)	-RRB-	0	0	0	0	0	0	0	I-protein
protein	NN	0	0	0	0	0	0	1	I-protein
selectively	RB	0	0	0	0	0	0	1	O
induces	VBZ	0	0	0	0	0	0	1	O
apoptosis	NN	0	0	0	0	0	0	1	O
in	IN	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
malignant	JJ	0	0	0	0	0	0	1	B-cell_type
cells	NNS	0	0	0	0	0	0	1	I-cell_type
.	0	0	0	0	0	0	0	0	O
However	RB	0	0	0	0	1	0	0	O
,	,	0	0	0	0	0	0	0	O
for	IN	0	0	0	0	0	0	1	O
an	DT	0	0	0	0	0	0	1	O
effective	JJ	0	0	0	0	0	0	1	O
in	FW	0	0	0	0	0	0	1	O
vivo	FW	0	0	0	0	0	0	1	O
tumor	NN	0	0	0	0	0	0	1	O
treatment	NN	0	0	0	0	0	0	1	O
strategy	NN	0	0	0	0	0	0	1	O
,	,	0	0	0	0	0	0	0	O
an	DT	0	0	0	0	0	0	1	O
oncolytic	JJ	0	0	0	0	0	0	1	O
agent	NN	0	0	0	0	0	0	1	O
also	RB	0	0	0	0	0	0	1	O
needs	VBZ	0	0	0	0	0	0	1	O
to	TO	0	0	0	0	0	0	1	O
induce	VB	0	0	0	0	0	0	1	O
a	DT	0	0	0	0	0	0	1	O
potent	JJ	0	0	0	0	0	0	1	O
anti-tumor	JJ	0	0	1	0	0	0	0	O
immune	JJ	0	0	0	0	0	0	1	O
response	NN	0	0	0	0	0	0	1	O
.	0	0	0	0	0	0	0	0	O
In	IN	0	0	0	0	1	0	0	O
the	DT	0	0	0	0	0	0	1	O
present	JJ	0	0	0	0	0	0	1	O
study	NN	0	0	0	0	0	0	1	O
,	,	0	0	0	0	0	0	0	O
we	PRP	0	0	0	0	0	0	1	O
used	VBD	0	0	0	0	0	0	1	O
poly	NN	0	0	0	0	0	0	1	O
(	-LRB-	0	0	0	0	0	0	0	O
I	PRP	0	0	0	0	1	1	0	O
:	:	0	0	0	0	0	0	0	O
C	NN	0	0	0	0	1	1	0	O
)	-RRB-	0	0	0	0	0	0	0	O
,	,	0	0	0	0	0	0	0	O
a	DT	0	0	0	0	0	0	1	O
TLR3	NN	0	1	0	0	1	0	0	B-protein
ligand	NN	0	0	0	0	0	0	1	I-protein
,	,	0	0	0	0	0	0	0	O
as	IN	0	0	0	0	0	0	1	O
an	DT	0	0	0	0	0	0	1	O
adjuvant	JJ	0	0	0	0	0	0	1	O
along	IN	0	0	0	0	0	0	1	O
with	IN	0	0	0	0	0	0	1	O
CPV2.NS1	NN	0	1	0	0	1	0	0	B-protein
to	TO	0	0	0	0	0	0	1	O
find	VB	0	0	0	0	0	0	1	O
out	RP	0	0	0	0	0	0	1	O
if	IN	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
combination	NN	0	0	0	0	0	0	1	O
can	MD	0	0	0	0	0	0	1	O
enhance	VB	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
oncolytic	JJ	0	0	0	0	0	0	1	O
activity	NN	0	0	0	0	0	0	1	O
by	IN	0	0	0	0	0	0	1	O
inducing	VBG	0	0	0	0	0	0	1	O
a	DT	0	0	0	0	0	0	1	O
potent	JJ	0	0	0	0	0	0	1	O
anti-tumor	JJ	0	0	1	0	0	0	0	O
immune	JJ	0	0	0	0	0	0	1	O
response	NN	0	0	0	0	0	0	1	O
.	0	0	0	0	0	0	0	0	O
The	DT	0	0	0	0	1	0	0	O
4T1	NN	0	1	0	0	0	0	0	B-cell_line
mammary	JJ	0	0	0	0	0	0	1	I-cell_line
carcinoma	NN	0	0	0	0	0	0	1	I-cell_line
cells	NNS	0	0	0	0	0	0	1	I-cell_line
were	VBD	0	0	0	0	0	0	1	O
used	VBN	0	0	0	0	0	0	1	O
to	TO	0	0	0	0	0	0	1	O
induce	VB	0	0	0	0	0	0	1	O
mammary	JJ	0	0	0	0	0	0	1	O
tumor	NN	0	0	0	0	0	0	1	O
in	IN	0	0	0	0	0	0	1	O
Balb	c	0	0	0	0	1	0	0	O
mice	NNS	0	0	0	0	0	0	1	O
.	0	0	0	0	0	0	0	0	O
The	DT	0	0	0	0	1	0	0	O
results	NNS	0	0	0	0	0	0	1	O
suggested	VBD	0	0	0	0	0	0	1	O
that	IN	0	0	0	0	0	0	1	O
poly	NN	0	0	0	0	0	0	1	O
(	-LRB-	0	0	0	0	0	0	0	O
I	PRP	0	0	0	0	1	1	0	O
:	:	0	0	0	0	0	0	0	O
C	NN	0	0	0	0	1	1	0	O
)	-RRB-	0	0	0	0	0	0	0	O
,	,	0	0	0	0	0	0	0	O
when	WRB	0	0	0	0	0	0	1	O
given	VBN	0	0	0	0	0	0	1	O
along	RP	0	0	0	0	0	0	1	O
with	IN	0	0	0	0	0	0	1	O
CPV2.NS1	NN	0	1	0	0	1	0	0	B-protein
,	,	0	0	0	0	0	0	0	O
not	RB	0	0	0	0	0	0	1	O
only	RB	0	0	0	0	0	0	1	O
significantly	RB	0	0	0	0	0	0	1	O
reduced	VBD	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
tumor	NN	0	0	0	0	0	0	1	O
growth	NN	0	0	0	0	0	0	1	O
but	CC	0	0	0	0	0	0	1	O
also	RB	0	0	0	0	0	0	1	O
augmented	VBD	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
immune	JJ	0	0	0	0	0	0	1	O
response	NN	0	0	0	0	0	0	1	O
against	IN	0	0	0	0	0	0	1	O
tumor	NN	0	0	0	0	0	0	1	B-protein
antigen	NN	0	0	0	0	0	0	1	I-protein
(	-LRB-	0	0	0	0	0	0	0	O
s	NNS	0	0	0	0	0	0	1	O
)	-RRB-	0	0	0	0	0	0	0	O
as	IN	0	0	0	0	0	0	1	O
indicated	VBN	0	0	0	0	0	0	1	O
by	IN	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
increase	NN	0	0	0	0	0	0	1	O
in	IN	0	0	0	0	0	0	1	O
blood	NN	0	0	0	0	0	0	1	B-cell_type
CD4	NN	0	1	0	0	1	0	0	I-cell_type
+	CC	1	0	0	0	0	0	0	I-cell_type
and	CC	0	0	0	0	0	0	1	I-cell_type
CD8	NN	0	1	0	0	1	0	0	I-cell_type
+	CC	1	0	0	0	0	0	0	I-cell_type
counts	NNS	0	0	0	0	0	0	1	I-cell_type
and	CC	0	0	0	0	0	0	1	O
infiltration	NN	0	0	0	0	0	0	1	O
of	IN	0	0	0	0	0	0	1	O
immune	JJ	0	0	0	0	0	0	1	B-cell_type
cells	NNS	0	0	0	0	0	0	1	I-cell_type
in	IN	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
tumor	NN	0	0	0	0	0	0	1	O
tissue	NN	0	0	0	0	0	0	1	O
.	0	0	0	0	0	0	0	0	O
Further	RB	0	0	0	0	1	0	0	O
,	,	0	0	0	0	0	0	0	O
blood	NN	0	0	0	0	0	0	1	O
serum	NN	0	0	0	0	0	0	1	O
analysis	NN	0	0	0	0	0	0	1	O
of	IN	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
cytokines	NNS	0	0	0	0	0	0	1	B-protein
revealed	VBD	0	0	0	0	0	0	1	O
that	IN	0	0	0	0	0	0	1	O
Th1	NN	0	1	0	0	1	0	0	B-protein
cytokines	NNS	0	0	0	0	0	0	1	I-protein
(	-LRB-	0	0	0	0	0	0	0	O
IFN-Î	NN	0	0	1	0	1	0	0	B-protein
³	NN	0	0	0	0	0	0	0	I-protein
and	CC	0	0	0	0	0	0	1	O
IL-2	NN	0	1	1	0	1	0	0	B-protein
)	-RRB-	0	0	0	0	0	0	0	O
were	VBD	0	0	0	0	0	0	1	O
significantly	RB	0	0	0	0	0	0	1	O
upregulated	VBN	0	0	0	0	0	0	1	O
in	IN	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
treatment	NN	0	0	0	0	0	0	1	O
group	NN	0	0	0	0	0	0	1	O
indicating	VBG	0	0	0	0	0	0	1	O
activation	NN	0	0	0	0	0	0	1	O
of	IN	0	0	0	0	0	0	1	O
cell-mediated	JJ	0	0	1	0	0	0	0	O
immune	JJ	0	0	0	0	0	0	1	O
response	NN	0	0	0	0	0	0	1	O
.	0	0	0	0	0	0	0	0	O
The	DT	0	0	0	0	1	0	0	O
present	JJ	0	0	0	0	0	0	1	O
study	NN	0	0	0	0	0	0	1	O
reports	VBZ	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
efficacy	NN	0	0	0	0	0	0	1	O
of	IN	0	0	0	0	0	0	1	O
CPV2.NS1	NN	0	1	0	0	1	0	0	B-protein
along	IN	0	0	0	0	0	0	1	O
with	IN	0	0	0	0	0	0	1	O
poly	NN	0	0	0	0	0	0	1	O
(	-LRB-	0	0	0	0	0	0	0	O
I	PRP	0	0	0	0	1	1	0	O
:	:	0	0	0	0	0	0	0	O
C	NN	0	0	0	0	1	1	0	O
)	-RRB-	0	0	0	0	0	0	0	O
not	RB	0	0	0	0	0	0	1	O
only	RB	0	0	0	0	0	0	1	O
in	IN	0	0	0	0	0	0	1	O
inhibiting	VBG	0	0	0	0	0	0	1	O
the	DT	0	0	0	0	0	0	1	O
mammary	JJ	0	0	0	0	0	0	1	O
tumor	NN	0	0	0	0	0	0	1	O
growth	NN	0	0	0	0	0	0	1	O
but	CC	0	0	0	0	0	0	1	O
also	RB	0	0	0	0	0	0	1	O
in	IN	0	0	0	0	0	0	1	O
generating	VBG	0	0	0	0	0	0	1	O
an	DT	0	0	0	0	0	0	1	O
active	JJ	0	0	0	0	0	0	1	O
anti-tumor	JJ	0	0	1	0	0	0	0	O
immune	JJ	0	0	0	0	0	0	1	O
response	NN	0	0	0	0	0	0	1	O
without	IN	0	0	0	0	0	0	1	O
any	DT	0	0	0	0	0	0	1	O
visible	JJ	0	0	0	0	0	0	1	O
toxicity	NN	0	0	0	0	0	0	1	O
.	0	0	0	0	0	0	0	0	O
The	DT	0	0	0	0	1	0	0	O
results	NNS	0	0	0	0	0	0	1	O
of	IN	0	0	0	0	0	0	1	O
our	PRP$	0	0	0	0	0	0	1	O
study	NN	0	0	0	0	0	0	1	O
may	MD	0	0	0	0	0	0	1	O
help	VB	0	0	0	0	0	0	1	O
in	IN	0	0	0	0	0	0	1	O
developing	VBG	0	0	0	0	0	0	1	O
CPV2.NS1	NN	0	1	0	0	1	0	0	B-protein
and	CC	0	0	0	0	0	0	1	O
poly	NN	0	0	0	0	0	0	1	O
(	-LRB-	0	0	0	0	0	0	0	O
I	PRP	0	0	0	0	1	1	0	O
:	:	0	0	0	0	0	0	0	O
C	NN	0	0	0	0	1	1	0	O
)	-RRB-	0	0	0	0	0	0	0	O
combination	NN	0	0	0	0	0	0	1	O
as	IN	0	0	0	0	0	0	1	O
a	DT	0	0	0	0	0	0	1	O
cancer	NN	0	0	0	0	0	0	1	O
therapeutic	JJ	0	0	0	0	0	0	1	O
regime	NN	0	0	0	0	0	0	1	O
to	TO	0	0	0	0	0	0	1	O
treat	VB	0	0	0	0	0	0	1	O
various	JJ	0	0	0	0	0	0	1	O
malignancies	NNS	0	0	0	0	0	0	1	O
.	0	0	0	0	0	0	0	0	O
KEYWORDS	NNS	0	0	0	0	1	1	0	O
:	:	0	0	0	0	0	0	0	O
Anti-tumor	JJ	0	0	1	0	1	0	0	O
immune	JJ	0	0	0	0	0	0	1	O
response	NN	0	0	0	0	0	0	1	O
;	:	0	0	0	0	0	0	0	O
Apoptosis	NN	0	0	0	0	1	0	0	O
;	:	0	0	0	0	0	0	0	O
Breast	NN	0	0	0	0	1	0	0	B-protein
cancer	NN	0	0	0	0	0	0	1	O
;	:	0	0	0	0	0	0	0	O
Cancer	NNP	0	0	0	0	1	0	0	O
vaccine	NN	0	0	0	0	0	0	1	O
adjuvant	JJ	0	0	0	0	0	0	1	O
;	:	0	0	0	0	0	0	0	O
NS1	NN	0	1	0	0	1	0	0	B-DNA
;	:	0	0	0	0	0	0	0	I-DNA
Poly	NNP	0	0	0	0	1	0	0	I-DNA
(	-LRB-	0	0	0	0	0	0	0	I-DNA
I	PRP	0	0	0	0	1	1	0	I-DNA
:	:	0	0	0	0	0	0	0	I-DNA
C	NN	0	0	0	0	1	1	0	I-DNA
)	-RRB-	0	0	0	0	0	0	0	I-DNA
;	:	0	0	0	0	0	0	0	I-DNA
TLR3	NN	0	1	0	0	1	0	0	I-DNA
.	0	0	0	0	0	0	0	0	O
